S
terol O-acyltransferases (SOATs) are microsomal proteins responsible for catalyzing intracellular cholesterol ester (CE) synthesis using free sterol and acyl coenzyme A as substrates. 1 SOAT subtype1 (SOAT1) is expressed in a variety of tissues while SOAT subtype2 (SOAT2) is expressed preferentially in enterocytes of the intestine and hepatocytes of the liver, 2 where one of its roles is to generate CE for packaging into chylomicrons and very-low-density lipoproteins (VLDL), respectively.
3,4 CE, especially cholesterol oleate, are major components of atherogenic lipoproteins, appearing to play a critical role in the pathogenesis of atherosclerosis. 5, 6 Previous studies have shown that SOAT2-deficient animals had delayed atherosclerosis development. Global deletion of SOAT2 in low-density lipoprotein receptor null (LDLr −/− ) or apolipoprotein E null mice resulted in highly significant reductions of aortic atherosclerosis lesion area with a reduction in CE deposited in atherosclerotic plaques. 7, 8 These observed phenotypes are attributed to the combined effects of the decreased capability of cholesterol esterification and secretion by both the liver and the intestine, leading to a less atherogenic lipoprotein profile. However, some evidence has suggested that hepatic SOAT2 expression and activity in humans are different from that in rodents and nonhuman primates and might be expressed at a relatively lower level. [9] [10] [11] Relevant to the human condition, it is uncertain whether blocking cholesterol absorption alone through inhibiting intestinal SOAT2 would be sufficient to delay atherosclerosis progression.
Through LoxP-Cre recombinase technologies, our group previously generated 2 novel SOAT2 conditional knockout mice, the liver-specific (SOAT2 L−/L− ) and the intestine-specific (SOAT2 SI−/SI− ) knockouts. 12 In response to increased dietary cholesterol, plasma and hepatic lipid changes of SOAT2 SI−/SI− mice, indicated by low plasma VLDL cholesterol, low hepatic total cholesterol (TC), and CE concentrations, 12 were essentially the same as occurred in SOAT2 L−/L− mice. The data suggest that elimination of intestinal cholesterol esterification with subsequent absorption was sufficient to alleviate many of the dietary cholesterol-induced changes in cholesterol transport in the circulation and tissues.
Although the blunted cholesterol absorption that occurred via intestinal SOAT2 inhibition was hypocholesterolemic, the specific contribution made by intestine-derived CE to atherosclerosis development is still uncertain. LDLr −/− mice are known to develop a spectrum of cholesterol-enriched apolipoprotein B-containing lipoproteins, most of which apparently promote progression of atherosclerosis on high-fat/cholesterol-enriched diet. 13 The mass and distribution of plasma lipids of LDLr −/− mice are marked and distinct from the relatively mild elevation of lipids after high cholesterol intake by wild-type mice. It is unknown whether, after cholesterol feeding, SOAT2
SI−/SI− LDLr −/− mice would be protected from atherosclerosis progression to the same extent as that of LDLr −/− mice with gene deletions of either hepatic SOAT2 or whole body SOAT2. 14 We think it is critically important to understand the tissuespecific roles for SOAT2 in atherosclerosis development if effective therapeutic strategies targeting SOAT2-driven cholesterol esterification are to be designed. This prompted us to cross tissue-specific SOAT2 knockouts with LDLr −/− mice. Here, we tested whether conditional knockout of hepatic SOAT2 versus intestinal SOAT2 similarly limit atherosclerosis development compared with the global deletion of SOAT2.
Methods

Mice, Diet, and Study Design
Generation of tissue-specific SOAT2 knockouts was described in detail previously. 12 ). Both male and female mice were included in the study. At the age of 8 to 9 weeks, mice were fed a semisynthetic diet containing fat (as lard) at 20% energy, protein 17% energy, carbohydrate 63% energy, and cholesterol 0.1% (wt/wt) for a total of 16 weeks. Blood was drawn at baseline, 8 weeks, and 16 weeks from mice that were fasted at 9 am with blood collection from the superficial temporal vein starting at 1 pm. After consuming the diet for 8 weeks, mice were housed individually on wire bottom cages for 3 days to allow fecal collections for measurement of cholesterol absorption and fecal sterol loss. 15 For necropsy at the end of the study, mice were fasted from 9 am with terminations starting at 1 pm. All mice used in the studies were housed in a pathogen-free barrier facility at Wake Forest University School of Medicine approved by the American Association for Accreditation of Laboratory Animal Care. The Institutional Animal Care and Use Committee approved all protocols for use of animals before execution of the studies.
Plasma Lipid and Lipoprotein Analysis
Total plasma cholesterol (TPC) and triglyceride concentrations were measured using colorimetric enzymatic assays as previously described. 7, 15, 16 For lipoprotein measurement, an aliquot of plasma containing ≈20 µg of TPC was diluted in PBS into a final volume of 400 µL. After centrifugation to remove any protein precipitates, samples were injected onto a Superose 6 HR 10/30 (Amersham Pharmacia) chromatography column, which was subsequently run at 0.4 mL/min. The signal was integrated using Chrom Perfect Spirit Software (Justice Laboratory Software). VLDL-, LDL-, and high-density lipoprotein cholesterol were determined by multiplying the TPC concentration by the cholesterol percentage within the elution region for each lipoprotein class.
LDL Isolation and CE Analysis
For isolated LDL, a narrow center of the LDL peak window (26-34 minutes) was collected for each sample. Total lipid of this LDL fraction was extracted with 6 mL chloroform/methanol (2:1), and phases were split with 0.7 mL H 2 O. After vortexing and centrifugation, the chloroform phase was recovered and dried down under nitrogen and then dissolved in 1 mL chloroform/methanol (1:1) and stored at -20 o C until analysis. Fifty microliter of LDL lipid extract (≈15 µg/µL per sample) was diluted in 500 µL methanol containing 500 pg/µL of cholesterol heptadecanoate (Nu-Chek Prep) as an internal standard and 1 ng/µL of sodium formate. After standing for 30 minutes, the solution was analyzed by direct infusion into a Waters Quattro II tandem mass spectrometer operated at a flow rate of 10 µL/min in the positive ion mode. CE species were quantified with a response curve against 0.78 µmol/L internal standard as described elsewhere. 
Cholesterol Absorption Measurement by a Fecal Dual-Isotope Technique
The method was essentially as reported earlier by Temel et al. H]-sitosterol (New England Nuclear) and were subsequently individually housed in wired-bottom cages with free access to food and water. Feces were collected for a total of 3 days and dried overnight in a vacuum oven at 70 o C. Dried fecal pellets were crushed into fine powder, and ≈50 mg of fecal samples, along with 100 µg 5-α cholestane (as an internal standard), were saponified and extracted with hexane. For fractional cholesterol absorption, an aliquot of hexane phase was dried under nitrogen. The radioactivity was quantified in a liquid scintillation spectrometer (Beckman Coulter LS 6500), and percentage of cholesterol absorption was calculated as 100 × ( H in dose). Another aliquot of hexane phase was transferred to a gas-liquid chromatography vial, and fecal neutral sterol (FNS) was quantified by gas-liquid chromatography. The mass of FNS represented the sum of cholesterol and coprostanol, and results were expressed as mg sterol per day per 100 g body weight. 
Hepatic and Biliary Lipid Analysis
Extraction of liver and biliary lipids for enzymatic quantification of total triglyceride, CE, free cholesterol (FC), phospholipids and bile acids were performed as previously described. 7, 15 Briefly, for analysis of the liver lipids ≈50 to 100 mg of liver sample was minced and thawed in a glass tube. Lipids were extracted in chloroform/methanol (2:1) at room temperature overnight. Lipid extract was dried down under nitrogen and redissolved in a measured volume of 2:1 chloroform/methanol. After addition of 0.05% H 2 SO 4 and centrifugation, the aqueous upper phase was aspirated and discarded, and an aliquot of the bottom phase was transferred and dried down; 1% Triton X-100 in chloroform was then added, and the solvent was evaporated. Deionized water was then added to each tube and vortexed until the solution was clear. Lipids were quantified using available enzymatic assay kits. For analysis of biliary lipid concentrations, a measured volume (5-10 µL) of bile was placed into a glass tube and the lipids were extracted in chloroform/methanol (2:1). An aliquot of chloroform phase was used for quantification of biliary cholesterol and phospholipids, similarly as described for liver lipid measurement. An aliquot of the aqueous phase of the extraction was analyzed for total bile acid content using hydroxysteroid dehydrogenase-based enzymatic assay.
Quantification (En Face) of Aortic Lesion
At the time of necropsy, the entire length of aorta was excised and submersion fixed in 10% formalin for ≥24 hours. Adherent adipose and connective tissue were removed before the measurement. The aortas were opened longitudinally along the ventral midline and then pinned flat. Images of the aortas were captured using a Sony digital camera (Model DXC-S500) and evaluated for lesion extent using Scion Image software (Version 1.62). Percent of surface area occupied by lesion was calculated and expressed as percentage of surface area with visible atherosclerotic lesion. 
Quantification of Cholesterol in the Aortic Plaques
Lipids of the fixed entire aorta were then extracted in chloroform/ methanol (2:1) overnight together with addition of 20 µg of 5-α cholestane as an internal standard. 7 Aortic protein was then washed twice with chloroform/methanol (2:1), and pooled solvent with all lipids was evaporated under nitrogen. Dried lipids were dissolved in 250 µL hexane, and 1 µL of hexane phase was injected onto ZB-50 gas-liquid chromatography column to measure FC. After the FC quantification, the remaining samples were saponified and TC of aortas was also determined by gas-liquid chromatography. Aortic CE was calculated using the equation (TC-FC)×1.67.
Statistical Analyses
All graphs were plotted using GraphPad Prism (version 5. Table 1 ). LDLr −/− mice with SOAT2 intact had significant time-dependent increases of TPC after 8 and 16 weeks of consumption of the cholesterol-enriched diet (Table 1) To examine possible genetic responses that could be related to the hypertriglyceridemia in the SI−/SI− mice, we examined gene expression levels for several genes in liver and intestine of animals fed for 16 weeks. The data are in Online Table I and show that the only significant differences observed were in stearoyl-CoA desaturase 1 (SCD1) which was elevated over 10-fold in the intestine of whole body and intestine-specific SOAT2 gene deleted animals. Significant differences were not seen in the livers of these animals. Understanding of relationship between intestinal SCD-1 and hypertriglyceridemia in mice with intestinal SOAT2 deficiency will require further study. CE compositions were also measured in plasma LDL of all LDLr −/− mouse groups of the study ( Figure 2B ; Table 2 ). Groups with SOAT2 gene deletions had significantly lower percentages of saturated and monounsaturated fatty acids and higher percentages of polyunsaturated fatty acids ( Figure 2B ). These differences were most remarkable in mice with no hepatic SOAT2 (ie, SOAT2 Table 2 ) while percentages of linoleic acid (C18:2), arachidonic acid (C20:4), eicosapentaenoic acid (C20:5), and docosahexaenoic acid (C22:6) all were increased in LDL CE of mice with SOAT2 gene deletions, compared with LDL CE in LDLr −/− mice having intact SOAT2 ( Table 2 ). The extent of the decrease in the proportion of monounsaturated CE (and increase in polyunsaturated CE) was intermediate in the LDL of SOAT2 SI−/SI− mice.
SOAT2 Knockout Mice Have Lower Plasma VLDL and LDL Cholesterol Concentrations
Both Intestine-and Liver-Specific SOAT2 Knockout Mice Are Protected From Diet-Induced Hepatic Cholesterol Accumulation
Liver weight and body weight were not different among genotypes at the time of necropsy (Online Figure II) . SOAT2 ; TC, total cholesterol; and TG, triglycerides. October 24, 2014 while SOAT2 conditional knockouts had similar hepatic FC and triglyceride as control mice ( Figure 3C and 3D) . The concentration of phospholipid (PL) was not significantly different among any of the genotypes (data not shown). Figure 5B ). Regression analysis showed that the percentage of aortic surface area as lesion was significantly associated with aortic CE concentration (r=0.86, P<0.0001; data not shown). Furthermore, the percentage of monounsaturated CEs in LDL was significantly correlated with aortic CE concentration (r=0.74, P<0.0001; Online Figure  IV ) and with aortic surface area occupied with lesion (r=0.58, P<0.0001; Figure 5C ). The importance of LDL CE composition as a contributor to atherogenesis in addition to LDL cholesterol concentration can be appreciated when comparisons between the regressions of LDL cholesterol and LDL CE composition with atherogenesis (in this case expressed as aortic CE concentration) were made (Online Figure IV) . Both end points for LDL are significantly related to the extent of atherosclerosis, but the CE composition of LDL seems to be the more highly associated.
Intestinal SOAT2, But Not Liver SOAT2, Is a Critical Determinant of Biliary Cholesterol Levels
Discussion
Previous work from our laboratory has consistently shown that mice with whole body SOAT2 gene deletions are protected against atherosclerosis development.
7,8 Because SOAT2 is selectively expressed in only 2 tissues, the liver and the intestine, 2,11 both of which are lipoprotein CE secreting organs, we felt that it would be informative to determine if there were differences in the effect on atherosclerosis of having SOAT2 deletions separately in either of these tissues. To achieve this, the SOAT2 deletions need to be expressed in an atherosclerosis-susceptible mouse model. Given the lipoprotein profile of LDL receptor-deficient versus apolipoprotein E-deficient mice, the 2 main mouse models of atherosclerosis susceptibility, we studied the LDL receptor-deficient mouse because the lipoprotein profile is typically more similar to that seen in humans and is the mouse model that we have most often used previously. Our data show that although there is a somewhat higher level (≈2×) of SOAT2 activity in the intestine than in the liver in mice, the CEs secreted into lipoproteins by the liver are expected to more readily distribute into the LDL, which are the lipoproteins that appear to circulate longer at higher concentrations in plasma during atherogenesis. Thus, given that this study was done in LDL receptor-deficient animals, the outcome will be characteristic of mice with higher LDL levels. We have studied the responses to dietary cholesterol in SOAT2 liver-and intestine-specific knockout mice with LDL receptors intact and have published our findings. 12 In this case, the deficiency of SOAT2 in either tissue resulted in a similar plasma phenotype, although the percentage of intestinal cholesterol absorption was significantly less in the SOAT2 SI−/SI− mice while the hepatic CE concentrations were lower in the SOAT2 L−/L− mice. Excessive circulating apolipoprotein B-containing lipoproteins, especially LDL, would be retained in the arterial intima 6 and may initiate atherogenesis. SOAT2 knockout animals have delayed atherosclerosis development that is presumably because of the loss of capability of esterification of cholesterol oleate and packaging of those CEs into potentially atherogenic lipoprotein particles. Interestingly, intestine SOAT2 knockouts in the study had significantly less aortic lesion area and cholesterol deposition regardless of similar total mass of plasma LDL as that found in control mice (Figure 2 ). The small but significant decrease in VLDL cholesterol (and possibly reduced VLDL cholesteryl oleate) in the SOAT2 Si/Si mice may contribute to the decrease in atherosclerosis in these animals. One recent study suggested that LDL core enrichment in cholesterol oleate led to intimal deposition in the aorta through LDL-proteogylcan binding. 6 LDL isolated from global SOAT2 knockouts had minimal cholesterol oleate in the core and had a lower affinity to bind to proteoglycan, 6 which could contribute to the delayed atherosclerosis development. This study pinpoints the critical importance of LDL cholesterol oleate, in addition to LDL cholesterol mass (Online Figure IV) , as a potential marker to predict the severity of the atherosclerosis. As discovered by Miller et al, 17 plasma cholesterol oleate and other SOAT2-derived CE are valuable in predicting a patient's possibility of having acute coronary syndrome during an attack of sudden chest pain. Furthermore, SOAT2-derived CEs have recently been identified as predictors of cardiovascular disease risk in a large unbiased human lipidomic study. 18 These results suggest that our current findings have broad implications in human disease. Our current study also greatly extends our understanding of distinct roles of liver-and intestine-derived CE in atherosclerosis progression. Although intestine-specific SOAT2 knockouts were protected from atherosclerosis development, protection was not to the extent seen in liver-specific SOAT2 and total body SOAT2 knockouts. The difference could be explained by the fact that intestinal knockouts still efficiently esterify cholesterol in the liver despite the reduction in intestinal cholesterol absorption. This speculation is supported by the fact that more cholesterol oleate was recovered in LDL-CE of SOAT2 SI−/SI− LDLr −/− mice than other 2 knockouts ( Table 2) .
One of the characteristic changes in plasma lipids was the significant increase of triglyceride in whole body SOAT2 knockout, antisense oligonucleotide-mediated hepatic SOAT2 knockdown, and liver-specific SOAT2 knockouts. 8, 14, 16, [19] [20] [21] Liver perfusion studies suggested that triglyceride is more available for secretion in the absence of hepatic SOAT2, resulting in a higher rate of mobilization of hepatic triglyceride. 16, 19 Interestingly, SOAT2
SI−/ SI−.
LDLr −/− mice appeared to have even higher plasma triglyceride than liver-specific SOAT2 knockouts. Absence of intestinal SOAT2 would generate the CE-poor chylomicrons, 4 and remnants delivered to the liver could possibly lead to a similar effect to increase triglyceride mobilization and packaging of more triglyceride into the newly synthesized VLDL and circulating LDL. Furthermore, it is uncertain whether the absence of SOAT2 in the intestine or liver would affect the activities of lipoprotein lipase and its activator apolipoprotein CII, or interaction with apolipoprotein E, which all contribute to apolipoprotein B-containing lipoprotein clearance and atherosclerosis progression. It is important to emphasize that the hypertriglyceridemia in SOAT2 knockout animals does not seem to contribute significantly to the development of atherosclerosis as all of the SOAT2 knockouts have elevated circulating triglyceride yet delayed atherosclerosis progression. The aforementioned mechanisms would warrant future studies, such as liver perfusion assay, for clarification. When we looked at gene expression differences (Online Table I ), a 10-fold higher level of SCD-1 mRNA was detected in the intestine of the SOAT2 SI−/SI− mice, suggesting that this effect is related to the hypertriglyceridemia of these animals although the mechanism for such an outcome is not clear.
Our previous publication 12 and current findings clearly show that liver-and intestine-derived CEs both contribute to cholesterol accumulation in the circulation and tissues. We have found that human hepatic SOAT2 is expressed in much lower abundance relative to human intestinal SOAT2 among surgical samples collected from bariatric patients (Rudel L.L., Fernandez A.Z., and Davis M.A., unpublished data, 2011). This suggests that pharmaceutical strategies for targeting intestinal SOAT2 possibly could achieve a modest cardioprotective effect. A recent study showed that a nonspecific SOAT1 and SOAT2 inhibitor not only limited aortic lesion size but modified the composition in preexisting atherosclerotic plaque of apolipoprotein E null mice during atherosclerosis regression. 22 However, it is noted that nonspecific SOAT inhibitors also reduce SOAT1 activity, which can lead to FC accumulation across all cell types, potentially causing cytotoxicity to the cells. In fact, SOAT1 deficiency did not prevent the development of atherosclerosis lesion in either apolipoprotein E null or LDLr −/− mice that had massive xanthomatosis. 23, 24 Discouraging findings of A-PLUS (the Avasimibe and Progression of Lesions on Ultrasound) and ACTIVATE (ACAT Intravascular Atherosclerosis Treatment Evaluation) studies 25, 26 also suggested that nonspecific SOAT inhibitors may not benefit patients by slowing atherosclerosis progression, although efficacy was not clearly apparent in either of these studies. The limited amount of data suggest that future studies to investigate advantages of developing highly selective SOAT2 inhibitors during atherosclerosis progression and regression could be informative. Furthermore, a sensitive and reliable marker, such as plasma cholesterol oleate percentage and concentration, would appear useful as a surrogate end point to evaluate disease severity and potential for treatment of atherosclerosis in patients with premature coronary heart disease. 17 Given the lower levels of SOAT2 in human liver relative to intestine, species differences need to be considered.
In conclusion, our data clearly demonstrate that both hepatic and intestinal SOAT2-derived CEs can promote the potentially atherogenic CE accumulation that occurs during atherosclerosis progression. The data suggest that SOAT2 in either liver or intestine could possibly be a pharmaceutical target for treatment of atherogenesis.
